IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

Rise and shine, everyone, another busy day is on the way. However, this is shaping up as a beautiful day as well, despite forecasts suggesting a cloud or two will later hover about. Right now, the ...

GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.

GSK gained that nod from the FDA in 2017 ... Some other key metrics favored AZ’s medicine. For example, 41% of those who took ...

Trial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate ...

New biologics such as GSK's Benlysta and AstraZeneca's Saphnelo, along with off-label drugs, have been the mainstay for ...

Drug maker GSK plc (GSK, GSK.L) announced Tuesday that Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple ...

Products including untaxed cigarettes, vapes and banned medicine were found during a shop search. GSK Liquor Stop on Dudley ...